Director
Janssen Pharmaceuticals, Inc.
Joel Swerdel, PhD MS MPH is a Director of Epidemiology Analytics at Janssen Research and Development, a Johnson and Johnson company. He is involved in many epidemiological research projects where he designs novel approaches for the use of standard OHDSI methods. He is currently working on designing a standard approach for developing and evaluating phenotypes algorithms used in observational research.
Prior to joining Janssen Research and Development, Joel was at the Rutgers School of Public Health where he conducted epidemiology research in the areas of cardiovascular disease and cancer. Prior to Rutgers, Joel was at Bristol-Myers Squibb in drug development research. Joel received a BA from Rutgers, an MS from the Medical College of Wisconsin, and an MPH from the Rutgers School of Public Health. He received his doctorate in epidemiology from the Rutgers School of Public Health where he used patient-level prediction to develop models for predicting incident heart failure in subjects previously diagnosed with atrial fibrillation.
